Pre-Open Stock Movers 06/29: (KNSA) (WKHS) (COTY) Higher; (ICPT) (HRTX) (BYND) Lower (more...)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. SPCX
3. MU
4. SPY
5. ACN
6. IBM
7. PRIM
8. PFE
9. TSLA
10. DPZ

Go back to Pre-Open Stock Movers 06/29: (KNSA) (WKHS) (COTY) Higher; (ICPT) (HRTX) (BYND) Lower (more...)

Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield

June 30, 2020 7:04 AM EDT

Altimmune, Inc. (NASDAQ: ALT) today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised.

NasoShield is the only single dose anthrax vaccine in development that is supported by BARDA, and has the potential to provide a significant improvement over the available two- and... More

Heron Therapeutics (HRTX) PT Lowered to $34 at Cowen; Launch Likely Pushed to Mid-2021

June 29, 2020 10:56 AM EDT

Cowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $34.00 (from $39.00) while maintaining an Outperform rating.

The analyst commented, "Heron received a CRL for HTX-011 requesting additional nonclinical information. The CRL is related to excipient exposure levels from... More